HEPA · Hepion Pharmaceuticals, Inc.
$0.05
+0.00 (+2.22%)
At close · Jul 30
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”View the 10-Q filed May 14, 2026
Market Cap
$1.34M
Shares
29.12M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gary S. Stetz, II | director | Appointed | 2026-07-02 |
| Danina Fisher | director | Appointed | 2026-07-02 |
| Kaouthar Lbiati | director | Resigned | 2026-04-14 |
| Chase LoPriore | director | Appointed | 2026-03-18 |
| Vincent LoPriore | Executive Chairman | Appointed | 2026-03-18 |
| Sireesh Appajosyula | director | Appointed | 2026-03-18 |
| Gary Stetz | director | Appointed | 2026-03-18 |
| Gary Stetz | interim Chief Executive Officer | Appointed | 2026-03-18 |
| Dr. Kaouthar Lbiati | Chief Executive Officer | Resigned | 2026-03-18 |
| Dr. Kaouthar Lbiati | Chief Executive Officer | Appointed | 2026-01-15 |
| John Brancaccio | director | Resigned | 2025-06-30 |
| John Brancaccio | CFO | Resigned | 2025-06-30 |
| Dr. Kaouthar Lbiati | interim Chief Executive Officer | Appointed | 2025-06-09 |